G
Gullu Gorgun
Researcher at Harvard University
Publications - 77
Citations - 5164
Gullu Gorgun is an academic researcher from Harvard University. The author has contributed to research in topics: Bortezomib & Stromal cell. The author has an hindex of 33, co-authored 77 publications receiving 4613 citations. Previous affiliations of Gullu Gorgun include Tufts Medical Center & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Alan G. Ramsay,Amy J. Johnson,Abigail M. Lee,Gullu Gorgun,Rifca Le Dieu,William Blum,John C. Byrd,John G. Gribben,John G. Gribben +8 more
TL;DR: Impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia exhibiting defective immunological synapse formation with APCs is demonstrated and repair of immune synapse defects is identified as an essential step in improving cancer immunotherapy approaches.
Journal ArticleDOI
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura,Mariateresa Fulciniti,Gullu Gorgun,Yu-Tzu Tai,Diana Cirstea,Loredana Santo,Yiguo Hu,Claire Fabre,Jiro Minami,Hiroto Ohguchi,Tanyel Kiziltepe,Hiroshi Ikeda,Yutaka Kawano,Maureen French,Martina Blumenthal,Victor Tam,Nathalie L. Kertesz,Uriel M. Malyankar,Mark Hokenson,Tuan Pham,Qingping Zeng,John B. Patterson,Paul G. Richardson,Nikhil C. Munshi,Nikhil C. Munshi,Kenneth C. Anderson +25 more
TL;DR: Results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.
Journal ArticleDOI
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Gullu Gorgun,Gregory Whitehill,Gregory Whitehill,Jennifer L. Anderson,Jennifer L. Anderson,Teru Hideshima,Craig Maguire,Jacob P. Laubach,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +12 more
TL;DR: Assessment of the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma and the immunomodulatory effects of lenalidomide and bortezomib suggest that inhibition of the tumor-promoting and immune-suppressive functions of M DSCs in MM may represent a promising novel immune-based therapeutic strategy.
Journal ArticleDOI
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
Gullu Gorgun,Tobias A. W. Holderried,David Zahrieh,Donna Neuberg,John G. Gribben,John G. Gribben +5 more
TL;DR: Identification of the specific pathways perturbed in the T cells of cancer-bearing patients will allow us to assess steps to repair these defects, which will likely be required to enhance antitumor immunity.
Journal ArticleDOI
Targeting the bone marrow microenvironment in multiple myeloma
Yawara Kawano,Michele Moschetta,Salomon Manier,Siobhan Glavey,Gullu Gorgun,Aldo M. Roccaro,Kenneth C. Anderson,Irene M. Ghobrial +7 more
TL;DR: The interaction between the malignant plasma cell and the BM microenvironment and the strategy to target them is discussed.